Retina

The Royal National Institute of the Blind (RNIB) require 300 patients and carers to participate in two research projects.

Retained viscoelastic at the graft-host interface during DSEK may cause a reticular interface haze that can compromise visual clarity.

Indocyanine green angiography (ICGA) correlate with OCT findings of polypoidal lesions in polypoidal choroidal vasculopathy.

Ranibizumab injections could cause geographic atrophy (GA) progression in eyes with choroidal neovascularisation (CNV).

Intravitreal anti-VEGF monotherapy is safe and effective in treatment-naïve subretinal neovascular membrane (SRNVM) secondary to macular telangiectasia (Mactel).

Phacoemulsification is linked to a higher rate of posterior capsule rupture in vitrectomized eyes, compared to combined vitrectomy and cataract surgery.

Prophylactic treatment of retinal breaks during vitrectomy appears to reduce the risk of postoperative retinal detachment (RD).

The National Institute for Health and Clinical Excellence (NICE) recommends the use of ranibizumab for patients with diabetic macular oedema (DME).

Decreased choroidal thickness could increase vascular endothelial growth factor (VEGF) and cause tissue hypoxia.

Fundus autofluorescence (FAF) imaging could be a useful tool for assessing patients with serpiginous choroidopathy (SC) and serpiginous-like choroidopathy (SLC).

The photoreceptor inner segment/outer segment (IS/OS) junction integrity can be affected by drusen evolution.

The Rapid Assessment of Avoidable Blindness (RAAB) framework can be used to assess diabetes and diabetic retinopathy (DR) but us costly and time consuming.

A ranibizumab and photodynamic therapy combination can improve visual acuity and reduce exudation in polypoidal choroidal vasculopathy.

Invitreal injection of ocriplasmin resolves vitremacular traction and closes macular holes.

Anti-VEGF therapy pegaptanib is efficacious and non-toxic for patients with retinopathy of prematurity (ROP), states a recent study.

Chronic diabetic macula oedema (DME) treatment Iluvien, developed by Alimera Sciences, has obtained marketing authorization in Germany.

Novartis sponsored a symposium at the COPHy congress in 2012 exploring the current treatment issues surrounding wet AMD. This supplement reveals the highlights of the meeting.

Intravitreal bevacizumab (IVB) provide sustained and effective treatment for myopic choroidal neovascularization (mCNV).

Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.

The microperimeter (MP-1) is ideal for detecting early retinal sensitivity loss in diabetic patients.

Intravitreal ranibizumab improves visual acuity and anatomic changes in AMD.

Fight for Sight has donated £1.6 million towards ten research grants focused on tackling sight loss and eye disease treatment.

JP Medical Ltd has announced the release of The Sclera and Systemic Disorders, available now.

A thin choroid at the upper border of the inferior staphyloma is linked to serous retinal detachment development.

The rate of change in flicker sensitivities is helpful in predicting geographic atrophy (GA)

It is possible for AMD patients to maintain BCVA for fives years after macular translocation surgery..

The combination of diabetes and hypertension-potentiated retinal oxidative and inflammatory stress accelerates retinal cell death and acellular capillary formation.

New anatomic characteristics of peripapillary intrachoroidal cavitation have been identified using optical coherence tomography (OCT).

The warning signs of childhood eye cancer retinoblastoma will be included in the new edition of the Personal Child Health Record.

Focal lamina cribrosa (LC) occurs in conjunction with neuroretinal rim and visual field loss.